Comprehensive coverage

Biotechnology cluster: Levitas Cardio recruits; And also on: Protlix, Yes Fit, Redhill Biopharma, Compugen and a joint venture with Germany in the field of biotechnology

In the medical trials: treatment of psoriasis, remission of Crohn's disease in children, and assistance in increasing immune tolerance
An energy transfer system for an artificial heart by Leviticos. PR photo

Leviticus Cardio completes a fundraising round of NIS 4 million

Leviticus Cardio, a portfolio company owned by the Trendlines Group, announces a fundraising round of approximately NIS 4 million. The company develops technology for transmitting wireless energy to the human body. The main product in which the company is concentrated are auxiliary devices for failing hearts called LVADs which with the company's technology will be wireless. The current round puts the amount of capital raised by the company so far at about NIS 7 million.

Leviticus, develops a solution for the wireless transfer of energy to operate implanted medical devices. The company is focused on developing the system for LVAD devices. Today these devices save the lives of many patients and are a preliminary or alternative solution to a heart transplant. The biggest drawback of LVAD today is the restrictive wired connection of the implanted device to external batteries and exposes it to infections. Leviticus' technology will enable a fully implantable system and significantly increase the market for LVAD. The market for LVAD devices is estimated at $3B today. The companies that manufacture LVAD today are: Heartware, Thoratec, Jarvik Heart, Circulite, Cleveland Heart, Sunshine Heart, Abiomed. Now, after presenting initial animal experiments, the company is turning to collaborations and pre-clinical experiments.

This week the company completed a fundraising round of approximately NIS 3 million - and obtained an agreement in principle to raise an additional NIS XNUMX million. The fundraising round was carried out by a group of American investors - represented in Israel by attorney Ronan Leffler - CEO of Inventionet. Some of the investors in this round are doctors who specialize in LVAD - which are a strategic asset to the company. Inventionet is now organizing another group of LVAD experts from the USA for the further investment.

Michael Zilbershlag, founder and CEO of Leviticus Cardio: "Transferring wireless energy to the human body with the efficiency of the company's CET technology changes the rules of the game in the LVAD market - and will enable a real quality of life for transplant recipients. Already today, the LVAD devices make it possible to save the lives of many patients, but the quality of life is a prerequisite for widespread use of the solution. The company presented at the last ISHLT conference the system works in animals and also presented the system with most of the LVAD devices that exist today and created a lot of interest that made the current recruitment possible."

Attorney Ronan Leffler - CEO of Inventionet: "Leuticus Cardio is an example of an impressive technology developed in Israel. The group of American investors represented by the Inventionet company - is very happy to put the capital and strategic connections at its disposal - in order to promote it."

Protelix announces positive results in a phase 1 trial of oral GCD in Gaucher patients

Protlix announced positive preliminary results in the company's Phase 1 clinical trial of oral glucocerebrosidase (GCD), or oral GCD, (PRX-112) in patients with Gaucher's disease.

In the oral GCD trial, it responded well, and an active enzyme was observed in the bloodstream of the GCD patients. Oral is a form available for oral intake of the enzyme expressed in plant cell culture - glucocerebrosidase, or GCD, which is the same active ingredient present in the alternative enzyme therapy (ERT) approved for marketing by the company - AllezoGCD. Pumi is an active form of the human glucocerebrosidase enzyme that undergoes encapsulation within the carrot cells where it is produced.

Elsvir consulting company presented Yes Faith to potential investors and partners

The Yesfit Biopharma Group, which develops and commercializes drugs in advanced clinical stages for inflammatory diseases and liver diseases, reports that the company's 101CF drug was selected as one of the ten most attractive opportunities in the field of inflammatory autoimmune diseases ("Top Autoimmune/Anti-Inflammatory Disease Projects to Watch") by Elsevier Business Intelligence, a global leader in the field of information about the medical industry.

The anti-inflammatory indications of the 101CF drug include psoriasis, for which the company is currently conducting a phase 2/3 trial in the USA, Europe and Israel. According to Global Data, the psoriasis market was valued at approximately $3.3 billion in 2010 and is expected to grow to approximately $6.7 billion in 2018. In addition, the company is conducting a phase 2 trial in arthritis in Europe and Israel, the results of which are expected to be published during the fourth quarter of this year. According to Global Data, the market for arthritis was estimated at about 12 billion dollars in 2010 and is expected to grow to about 18 billion dollars in 2020.
"It is a great honor to be selected as a leading project by Elsevier," said Prof. Panina Fishman, CEO of the Yes Fit Group, "This selection reaffirms the company's progress and the extensive product pipeline we are developing. We look forward to the publication of the results of the phase 2 trial in arthritis later this year."

Redhill Biopharma's RHB-104 combination achieved 80% remission results in an independent trial with children with Crohn's disease

The Israeli biopharmaceutical company, RedHill Biopharma (Biopharma RedHill), which develops patent-protected drugs in advanced clinical development stages, reports on a study that was presented at the annual scientific conference of the ACG (American College of Gastroenterology) on October 14, 2013 and will be published in the journal American Journal of Gastroenterology.

The company presented positive results in a retrospective, independent study, conducted in a single clinical center, in which 10 children with Crohn's disease were treated using an early formulation of Redhill's RHB-104 drug to kill the MAP bacteria (Mycobacterium avium subspecies paratuberculosis), which contained the same active ingredients in doses adapted to care for children. Crohn's disease is an inflammatory disease of the digestive system that has unanswered therapeutic needs.

The experiment was conducted by Professor Thomas Borody at the Center for Diseases of the Digestive System in Sydney, Australia, and was designed to test the safety and effectiveness of a treatment to kill the MAP bacteria as a treatment for Crohn's disease in children.

CompuGen Presents New Experimental Results Supporting CGEN-15001's Therapeutic Potential

Compugen reported results from an animal study in which CGEN-15001 was found to be effective in activating a mechanism that prevents the immune system from attacking the body itself, called immune tolerance. Activating this mechanism may lead to effective and safe treatment of a wide variety of autoimmune diseases resulting from a mistaken reaction of the immune system. The results will be presented tomorrow by Dr. Galit Rothman, the company's chief scientist, at an international conference of biomed industry leaders on autoimmune diseases and inflammation in Boston, Massachusetts. CGEN-15001 is a potential drug derived from a novel immune regulatory protein discovered by Compugen. The lecture will also include information on positive results of CGEN-15001 in the treatment of psoriasis in a disease model. These results expand the range of diseases that CGEN-15001 may treat.

Dr. Rothman will present the results of a recently completed bone marrow transplant trial. The trial shows that CGEN-15001 was highly effective in preventing graft rejection, a result that suggests that the drug works by activating the immune tolerance mechanism, which prevents the immune system from attacking the graft. Activating the immune tolerance mechanism is a central goal in the treatment of autoimmune diseases in which there is a need to inhibit the immune system attacking the body. Compared to existing therapeutic approaches that usually suppress the activity of the immune system comprehensively, creating immune tolerance will provide a long-term solution to the disease without jeopardizing the ability of the immune system to remain active and fight infections and malignant cells.

The bone marrow transplant trial was performed as part of Compugen's ongoing collaboration with Stephen Miller, professor of microbiology and immunology at Northwestern University School of Medicine, in the US.

Dr. Rothman will present the results of another recently completed study in a psoriasis disease model. The study was conducted in collaboration with Professor Amos Gilhar of the Technion, and it proves the potential of CGEN-15001 to treat this chronic and severe disease. The effect of CGEN-15001 was tested in a mouse model of human psoriasis, in which a piece of normal human skin is transplanted into mice with a weakened immune system and the disease is induced by injecting blood cells taken from psoriasis patients. The CGEN-15001 treatment by injection into the skin graft began at the same time as the injection of the blood cells, and after a certain period of time the pieces of skin were examined using a microscope for the characteristics of the psoriasis disease. The trial results show that treatment with CGEN-15001 prevented psoriasis with high efficiency. Currently there is no cure for psoriasis and the treatment may include steroid ointments, phototherapy, and systemic drugs that suppress the immune system.

The German government is launching a new economic venture to promote investments, development and trade in the field of biotech - Israel-Germany

The government's Ministry of Economy and Technology in Germany launched a new venture that will promote investments and trade in the field of biotech and which will focus on promoting joint Israeli and German activity in the field. The new project, which will be called Health - Made in Germany, will be operated by the German Economic Development Agency (GTAI) and will promote collaborations and investments in the life sciences industry, mainly in the fields of biotech in Israel. The new body was announced as part of the Life Sciences Israel TM business development conference that took place last week in "A.

The Health - Made in Germany program is headed by Dr. Mendri Tilo, Doctor of Laws and expert in medical and pharmaceutical law and chairman of the German-Israeli Committee for Life Sciences. Dr. Tilo is the representative of the government's Ministry of Economy and Technology in Germany, which together with the Agency for Economic Development in Germany, enjoy a close system of relationships with organizations that represent the health industry in over 50 countries in the world. The new body decided to promote and invest in Israeli companies from the field of life sciences, with the emphasis being precisely on the field of biotech, which in recent years has suffered from a severe lack of investments, grants and support.

Sigal Weisswasser, owner of TBN Group, which has been active in Germany for several years, the initiator and chairman of the conference: "Israel, which is considered one of the leading countries in the world in the field of innovation, research and development in the biopharma and medtech industry, is an important strategic partner for Germany, which represents the largest market in Europe , and one of the strongest markets in the world in the field of life sciences and medicine. In fact, Israel is the first country in the world with which Germany is promoting a unique research and development project with start-ups, universities, incubators, hospitals and more."

Leave a Reply

Email will not be published. Required fields are marked *

This site uses Akismat to prevent spam messages. Click here to learn how your response data is processed.